Table 2.
Immunohistochemistry
| Patient No.a (Age Range) | Histology | Immunohistochemistry | H3F3A results | |
|---|---|---|---|---|
| Pre-denosumab | Post-denosumab | |||
| Primary GCTB | ||||
| 1 (80–89 y) | Undifferentiated pleomorphic sarcoma | NA | NA | NA |
| 2 (50–59 y) | Undifferentiated spindle cell sarcoma | P63+, P53–, MDM2+/– (FISH not amplified) | P63–, P53−, MDM2+ (FISH not amplified) |
Pre-denosumab: H3F3A– Post-denosumab: NE |
| 3 (20–29 y) | Osteogenic sarcoma | KI67/MIB-1 40%, focally high, PDGFR-β+, PDGFR-α– | NA | NA |
| 4 (70–79 y) | Undifferentiated pleomorphic sarcoma | NA | MDM2– (FISH not available), P53–, P63–, SATB2− | NE |
| 5 (30–39 y) | Undifferentiated pleomorphic sarcoma | MDM2+/– (FISH not available) P53–, P63− | MDM2+(FISH not available), P53+, P63– | NE |
| Secondary GCTB | ||||
| 6 (40–49 y) | High-grade sarcoma | NA | NA | NA |
| 7 (40–49 y) | Undifferentiated pleomorphic sarcoma | Vimentin+, P63+, CD31–, CD34–, CKCAM5.2–, AE1–/AE3–, SMA–, S100–, and desmin– | NA | NA |
| 8 (40–49 y) | Undifferentiated pleomorphic sarcoma | NA | MDM2+/– (FISH not available), P53+/–, P63− | NA |
| 9 (20–29 y) | Giant cell tumor with suspect progression to sarcoma | MDM2+/– (FISH not available), P53+/–, P63+/–, SATB2+/– | NA | Pre-denosumab: H3F3A+ |
| 10 (50–59 y) | High-grade undifferentiated spindle cell sarcoma |
MDM2+ (FISH not available), P53–, P63+/–, SATB2+/– In recurrences: MDM2– (FISH not available), P53–, P63–, SATB2+/– |
MDM2+/– (FISH not available), P53+, P63+/–, SATB2– | Pre-denosumab: H3F3A+ (at initial diagnosis and recurrences) |
| Sarcomatous transformation | ||||
| 11 (30–39 y) | Undifferentiated spindle cell sarcoma | P63–, P53+/–, MDM2– (FISH not available); | P63–, P53+, MDM2+ (FISH not available) | NA |
| 12 (60–69 y) | High-grade osteosarcoma | P63+, P53+, MDM2+ (FISH not available) | P63–, P53+, MDM2+ (FISH not available) |
Pre-denosumab: H3F3A+ Post-denosumab: H3F3A+ |
| 13 (30–39 y) | Undifferentiated spindle cell sarcoma | P53+, MDM2+ (by FISH amplified) at malignant diagnosis but MDM2– (FISH not amplified) at initial GCTB diagnosis | NA | |
| 14 (50–59 y) | High-grade osteosarcoma | MDM2+/– (FISH not available), P53+/–, P63− | MDM2+ (FISH not available), P53–, P63+/–, SATB2+ | Pre-denosumab: H3F3A+ |
| Misdiagnoses | ||||
| 15 (20–29 y) | Giant cell-rich osteosarcoma | NA | SMA+/–, S100–, Ki67/MIB1 20%CD68+, vimentin+, focally positive for CD45 and SMA, S100–, CD30–, CD15–, Ki67 showed moderately high proliferative index | NA |
| 16 (70–79 y) | Pleomorphic rhabdomyosarcoma | P63–, P53+, MDM2+/– (FISH not available) | P63–, P53+, MDM2+ (by FISH not amplified), desmin+, myogenin+ | Pre-denosumab: H3F3A– |
| 17 (40–49 y) | Undifferentiated spindle cell sarcoma | CK AE1/AE3CD68+, vimentin++, cytokeratin AE 1/3+, S100– | NA | |
| 18 (20–29 y) | Osteogenic sarcoma (present pre-enrollment) | NA | NA | NA |
| 19 (10–19 y) | Phosphaturic mesenchymal tumor of mixed connective tissue type | NA | NA | NA |
| 20 (30–39 y) | Undifferentiated spindle cell sarcoma | NA | NA | NA |
CK cytokeratin, FISH fluorescence in situ hybridization, GCTB giant cell tumor of bone, MDM2 mouse double minute 2, NA not available, NE not evaluable, PDGFR platelet-derived growth factor receptors, SATB2 special AT-rich sequence-binding protein 2, SMA smooth muscle antibody
aPatient numbers and age ranges (in brackets), instead of age at treatment, are identifiers for the purposes of this publication only and do not link to patients